IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-4.35%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$222M
AUM Growth
–
Cap. Flow
+$226M
Cap. Flow %
102.02%
Top 10 Hldgs %
61.86%
Holding
49
New
49
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$20.2M
2
BIIB icon
Biogen
BIIB
+$19.5M
3
SHPG
Shire pic
SHPG
+$16.9M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$16.4M
5
GILD icon
Gilead Sciences
GILD
+$13.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$21M 9.48%
+181,722
New +$20.2M
2016 Q4
0 quarters
BIIB icon
2
Biogen
BIIB
$34.4B
$18.7M 8.42%
+65,908
New +$19.5M
2016 Q4
0 quarters
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$16.4M 7.38%
+133,841
New +$16.4M
2016 Q4
0 quarters
SHPG
4
DELISTED
Shire pic
SHPG
$16.2M 7.31%
+95,200
New +$16.9M
2016 Q4
0 quarters
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$12.7M 5.72%
+94,500
New +$11.9M
2016 Q4
0 quarters
GILD icon
6
Gilead Sciences
GILD
$190B
$12.6M 5.67%
+175,784
New +$13.1M
2016 Q4
0 quarters
REGN icon
7
Regeneron Pharmaceuticals
REGN
$80.1B
$11.9M 5.37%
+32,430
New +$12.3M
2016 Q4
0 quarters
AMGN icon
8
Amgen
AMGN
$230B
$11.7M 5.28%
+80,104
New +$12.1M
2016 Q4
0 quarters
ARIA
9
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$8.18M 3.69%
+657,912
New +$7.92M
2016 Q4
0 quarters
INCY icon
10
Incyte
INCY
$22.6B
$7.9M 3.56%
+78,775
New +$7.69M
2016 Q4
0 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$126B
$7.78M 3.5%
+105,522
New +$8.59M
2016 Q4
0 quarters
ENTL icon
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$7.63M 3.44%
+403,320
New +$7.74M
2016 Q4
0 quarters
ILMN icon
13
Illumina
ILMN
$41B
$7.16M 3.23%
+57,507
New +$7.75M
2016 Q4
0 quarters
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$10.7B
$6.27M 2.82%
+75,666
New +$6.51M
2016 Q4
0 quarters
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
$5.21M 2.35%
+138,000
New +$5.22M
2016 Q4
0 quarters
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$3.33M 1.5%
+75,000
New +$2.64M
2016 Q4
0 quarters
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.21M 1.45%
+29,555
New +$3.52M
2016 Q4
0 quarters
ADMS
18
DELISTED
Adamas Pharmaceuticals
ADMS
$3.13M 1.41%
+185,234
New +$2.86M
2016 Q4
0 quarters
LGND icon
19
Ligand Pharmaceuticals
LGND
$5.88B
$3.05M 1.37%
+48,090
New +$3.03M
2016 Q4
0 quarters
EXEL icon
20
Exelixis
EXEL
$15.1B
$2.76M 1.24%
+185,000
New +$2.67M
2016 Q4
0 quarters
FOMX
21
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.2M 0.99%
+197,838
New +$1.86M
2016 Q4
0 quarters
KALV icon
22
DELISTED
KalVista Pharmaceuticals
KALV
$2.19M 0.98%
+322,436
New +$2.38M
2016 Q4
0 quarters
VNDA icon
23
Vanda Pharmaceuticals
VNDA
$255M
$2.17M 0.98%
+135,817
New +$2.18M
2016 Q4
0 quarters
PRTA icon
24
Prothena Corp
PRTA
$430M
$2.07M 0.93%
+42,000
New +$2.32M
2016 Q4
0 quarters
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$13.6B
$1.98M 0.89%
+18,200
New +$2.03M
2016 Q4
0 quarters
1
2

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2016 Portfolio in Review

Q4 2016 is the first quarter with a 13F filing on record for International Biotechnology Trust, which disclosed 49 positions worth $222M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Celgene Corp: 181,722 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • International Biotechnology Trust's largest Q4 2016 buy was Celgene Corp: 181,722 shares worth $21M.
  • International Biotechnology Trust's ten largest holdings make up 62% of its $222M portfolio in Q4 2016.
  • International Biotechnology Trust disclosed 49 positions in Q4 2016, its first 13F filing on record.

Based on International Biotechnology Trust's 13F filing for Q4 2016, filed 2 Mar 2018.